Another company adds to the withdrawal of a drug that is usually prescribed to control high blood pressure and the type of heart failure
Legacy withdrawn medication is specifically Losartan Potásico.
All withdrawals are related to the detection of traces of a possible carcinogen.
Legacy Pharmaceutical Packaging said on Wednesday it had added a new batch to the Losartan reminder, adding to the three that had been removed from the shelves in a wave of reminders that began in the summer of 2018.
The medicine is usually prescribed for control of high blood pressure and the type of heart failure.
All downloads are related to the detection of traces of a possible carcinogen, called N-methylnitrosobutyric acid or NMBA, in the active ingredient of the drug.
NMBA, an impurity that can cause cancer, was found at levels above the usual levels set by the FDA, said Torrent last week and specified that no adverse effects have been reported so far. On the other hand, Legacy indicated that he had received no warning on each occasion.
Legacy Drug Retreat is special Losartan Potasico, USP, 50mg NDC 68645-494-54 and you can click here to see in detail all batch removed.
The affected patients were asked not to stop the treatment suddenly and establish their place to communicate with their physician to consult before stopping doses or to report any adverse effect.
Anyone who has questions can contact Torrent Pharmaceuticals on 1-800-912-9561 24.